Abstract. We reviewed the antibiotic susceptibility patterns of all isolates of Salmonella typhi in Ontario, Canada from January 2002 to December 2007. We identified a total of 381 unique cases over the 5-year period (50-73 cases per year). Of the 381 cases, 171 were female, 164 were male, and no gender was identified for 33 cases. Age of the patients ranged from less than 1 to 102 years of age (median age of 20 years). Although resistance patterns for ampicillin, trimethoprim-sulfamethoxazole, third generation cephalosporins (cefotaxime until May 2005 and ceftriaxone from June 2005 to present), and chloramphenicol remained stable, nalidixic acid resistance rose sharply between 2003 and 2005 and has remained at approximately 80% of isolates since 2005. The significant and sustained increase in nalidixic acid-resistant S. typhi suggests that ciprofloxacin should no longer be used as the drug of choice for the empiric treatment of typhoid fever in Ontario.
Abstract. We reviewed the antibiotic susceptibility patterns of all isolates of Salmonella typhi in Ontario, Canada from January 2002 to December 2007. We identified a total of 381 unique cases over the 5-year period (50-73 cases per year). Of the 381 cases, 171 were female, 164 were male, and no gender was identified for 33 cases. Age of the patients ranged from less than 1 to 102 years of age (median age of 20 years). Although resistance patterns for ampicillin, trimethoprim-sulfamethoxazole, third generation cephalosporins ( 1 Until the early 1990s, the treatment of choice for typhoid fever was ampicillin, choloramphenicol, or trimethoprim-sulfamethoxazole. However, because of increasing resistance to these drugs, ciprofloxacin replaced them as the drug of choice in the early 1990s, with good clinical efficacy. 2 Reduced susceptibility and in-vitro resistance to ciprofloxacin followed shortly thereafter, accompanied by clinical treatment failures. 3, 4 Reduced susceptibility to fluoroquinolones in Salmonella spp. most often arises from point mutations in the quinolone resistance determinant (QRDR) of the gyrA gene encoding the A subunit of DNA gyrase. In the microbiology laboratory, this is detected by resistance to nalidixic acid and increased minimum inhibitory concentration (MIC ) to ciprofloxacin, though ciprofloxacin usually remains within the susceptible range for Enterobactireaceae . 5 In 2003, the Clinical Laboratory Standards Institute (CLSI) included testing for resistance to nalidixic acid (nalidixic acid-resistant S. typhi , or NARST) as an indicator of reduced fluoroquinolone susceptibility in Salmonella spp. 6, 7 Salmonella typhi is considered to be resistant to naladixic acid at an MIC equal to or greater than 32 mg/L. It is considered to be intermediate to ciprofloxacin at an MIC equal to 2 mg/L and resistant at an MIC equal to or greater than 4 mg/L.
We reviewed the antibiotic susceptibility patterns of all unique isolates of S. typhi in Ontario, Canada from January 2002 to December 2007. In Ontario, all isolates of S. typhi are sent to the Central Public Health Laboratory (CPHL) for confirmatory identification and antibiotic susceptibility testing (AST). The AST was performed by agar dilution according to CLSI recommendations. 8 In June of 2003, nalidixic acid was added to the AST protocol for S. typhi. Isolates susceptible to ciprofloxacin, but resistant to nalidixic acid were reported as susceptible to ciprofloxacin with the following comment: "This strain is resistant to nalidixic acid. Fluoroquinolone-susceptible strains of Salmonella that test resistant to nalidixic acid may be associated with clinical failure or delayed response in fluoroquinolone-treated patients with extra-intestinal salmonellosis."
We identified a total of 381 unique cases over the 5-year period (50-73 cases per year, Figure 1 ). Of the 381 cases, 171 were female, 164 were male, and no gender was identified for 33 cases ( Figure 2 ) . Age of the patients ranged from less than 1 to 102 years of age (median age 20 years). During this period of time, there were no documented outbreaks of infection in Ontario. All cases were travel-related or linked to someone who had traveled. The significant and sustained increase in nalidixic acidresistant S. typhi suggests that ciprofloxacin should no longer be used as the drug of choice for the empiric treatment of typhoid fever in Ontario. Similar recommendations hold true for other settings including the United States, in which the majority of imported cases originate in travelers and immigrants from the Indian subcontinent, or where the prevalence of NARST in isolates of S. typhi is known to be high. 9 All individuals arriving from South Asia with typhoid fever should be considered at high risk for having a fluoroquinolone resistant strain of S. typhi . A recent prospective population-based study in five Asian countries confirmed that S. typhi resistance to naladixic acid is greater than 50% in both India and Pakistan. 10 In cases of fluoroquinolone resistance, therapeutic alternatives include a third generation cephalosporin, or azithromycin for those with a beta lactam allergy. It will be important to establish standardized interpretive criteria for AST of azithromycin with respect to Salmonella spp. Although azithromycin is recommended for the treatment of S. typhi infections, no AST guidelines exist at present.
Enteric fever caused by S. typhi remains an important clinical and public health problem which, as a result of travel and immigration, is not rare in the developed world. Given the documented ability of S. typhi to develop resistance to various antibiotics, it is important for clinicians to remain aware of changing trends in antimicrobial resistance of S. typhi to ensure appropriate therapy for this potentially fatal disease. 
